Mintzer S, Dimova S, Zhang Y, et al. - In adults with newly diagnosed epilepsy, researchers investigated serum lipid profiles after randomization to lacosamide (LCM) or carbamazepine (CBZ) monotherapy. Researchers examined data from a phase 3, international, randomized, double‐blind trial of LCM vs CBZ for the initial treatment of focal epilepsy. They examined serum lipid profiles in patients not taking lipid‐lowering agents and providing blood samples under fasting conditions before treatment and after 3 or 12 months of treatment with LCM or CBZ at various doses. For the analysis, 271 patients satisfied the inclusion criteria at 12 months. This research gives Class II evidence that CBZ increases serum lipids, whereas LCM has no impact on lipids. An increase of 21.1 mg/dL in total cholesterol, 12.6 mg/dL in low‐density lipoprotein (LDL) cholesterol, 12.5 mg/dL in non–high density lipoprotein (non‐HDL) cholesterol, and 8.5 mg/dL in HDL cholesterol was seen in CBZ‐treated patients; triglycerides remained unchanged. As per the findings, LCM was found to be an appropriate choice for new‐onset focal epilepsy.